 |
Biosketch
CURRICULUM VITAE
NAME: Charles Noah Bernstein
ADDRESS: University of Manitoba
Health Sciences Centre
804F-715 McDermot Avenue
Winnipeg, Manitoba, Canada R3E 3P4
Phone: 204 789-3369
FAX: 204 789-3972
Clinical trials office:
MS779 – 820 Sherbrook Street
Winnipeg, Manitoba, Canada R3A 1R9
Phone: 204 787-2060
FAX: 204 787-1843
E mail: cbernst@cc.umanitoba.ca
BIRTHDATE: 03/31/61
PLACE OF BIRTH: Winnipeg, Manitoba
CITIZENSHIP: Canadian
EDUCATION:
High School West Kildonan Collegiate Institute (1976-1979)
PreMedical School Faculty of Sciences (1979-1981)
University of Manitoba
Medical School Faculty of Medicine (1981-1985)
University of Manitoba
Elective Med IV: Respiratory Medicine
Cedars Sinai Medical Center
Los Angeles, California
Post Graduate Internship: Special Mixed Medicine (1985-1986)
University of Manitoba
Residency: Internal Medicine (1986-1989)
University of Manitoba
Elective: Gastroenterology (12/87-02/88)
Harbor UCLA Medical Center
Torrance, California
Fellowship: Gastroenterology (1989-1992)
UCLA Affiliated Training Program
in Gastrointestinal Diseases
CERTIFICATION, LICENSURE AND MEMBERSHIP
Certification:
• Licensure of the Medical Council of Canada (1985)
• National Board Examination (of America) (1986)
Internal Medicine Board Certification:
FRCPC: Internal Medicine-Royal College of Physicians and Surgeons of Canada
(Board certification, 1989)
Diplomate: American Board of Internal Medicine (1989)
(Certifying Examination - Score = 98 percentile)
Gastroenterology Board Certification:
FRCPC: Gastroenterology-Royal College of Physicians and Surgeons of Canada
(Board certification, 1991)
Diplomate: American Board of Internal Medicine, Gastroenterology (1991)
(Certifying Examination - Score = 96 percentile)
Licensure:
• The College of Physicians and Surgeons of Manitoba (1986-89, 1993- ) #13-016
• Licensure: State of California (1989-1994)
Memberships:
• American College of Gastroenterology (1999- )
• International Organization for the Study of Inflammatory Bowel Diseases (1999- )
• Canadian Medical Association (1993- )
• Manitoba Medical Association (1993- )
• Canadian Association of Gastroenterology (1992- )
• American Gastroenterology Association (1990- )
• American College of Physicians (1990-1996)
Appointments:
• Program Director, Gastroenterology Postgraduate Training Program, University of Manitoba, 2003-present
• Head, Section of Gastroenterology, University of Manitoba, 2001-present
• Professor of Medicine, University of Manitoba, 2001-present
• Associate Professor of Medicine, University of Manitoba, 1997-2001
• Director, University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, 1994-present
• Assistant Professor of Medicine, University of Manitoba, 1993-1997
• Associate Investigator, CURE: UCLA/VA Gastroenteric Biology Center, 1993-1998
• Assistant Professor of Medicine, University of California, Los Angeles, 1992
• Associate Director, U.C.L.A. Inflammatory Bowel Disease Center, 1992
• Clinical Instructor of Medicine, University of California, Los Angeles, 1991
• Gastroenterology Coordinator- U.C.L.A. Small Bowel Transplantation Program, 1991
AWARDS
High School - Grade XII (1978-1979)
• Seven Oaks School Board Scholarship
- (highest standing into Faculty of Arts & Sciences)
• Ian Dordick Memorial Award
- (highest standing - English)
• Institute of Chartered Accountants
- (highest standing - Mathematics)
• The Alumni Association of the University of Manitoba Award of Excellence
- (highest standing - Grade XII)
• Board of Governors Entrance Scholarship for High Standing
- Presented by the University of Manitoba Board of Governors
Faculty of Sciences - University of Manitoba (1979-1981)
• Alumni Association Scholarship for High Standing (Sciences I)
Morton Stall Memorial Book Prize in Biology
- (highest standing - Biology; Sciences I)
• Morton Stall Memorial Scholarship for Entrance to Medicine
- (highest G.P.A. for Entrants to Faculty of Medicine - Sciences II)
• Dr. Maxwell S. Rady Scholarship for Highest Standing (Sciences II)
Other
• Blinder Foundation Award- for Crohn's Disease Research (1991)
• Merck Sharpe and Dohme Postdoctoral Fellowship Award (1992)
• Canadian Association of Gastroenterology Young Clinicians Scholarship (1993)
• (elected) Fellow of American College of Gastroenterology (1999)
• Manitoba Medical Services Foundation Clinical Research Professorship (1999-2002)
• Nominated by Medicine II class for teacher of year (1998-1999)
• Rh Award for Outstanding Contributions to Scholarship and Research in the Health Sciences (2000)
• Crohn’s and Colitis Foundation of Canada Research Scientist Award (2001-2005)
• Nominated by Medicine II class for teacher of year (2000-2001)
• Crohn’s and Colitis Foundation of Canada Research Scientist Award (2006-2011)
GRANTS
1. UCLA Clinical Research Center (NIH Grant MO1 RR00865) 1991-1994. Principal Investigator. "Investigation of Bone Disease in Patients with Inflammatory Bowel Disease." $25,000
2. NIH Grant DK41301. Pilot and Feasability Award - CURE-UCLA Digestive Diseases Core Center Grant (1992) Principal investigator. "The Characterization of Murine Colonic Glial Cells." $15,000
3. University of Manitoba Research Grants Commitee (1993) Principal Investigator. "Adhesion Molecules in Inflammatory Bowel Disease." $3,300
4. University of Manitoba Radiology Fiscal Committee Grant (1994) Principal Investigator. "Small bowel enema versus small bowel follow-through in patients with Crohn's disease." $5,000
5. Manitoba Medical Services Foundation (1995). Principal Investigator. "Cell surface expression of inflammatory markers in inflammatory bowel disease: A longitudinal assessment of patients during disease activity and quiescence." $30,000
6. National Health and Research Development Program (1995-1997, #6607-1699-503). Principal Investigator "The epidemiology of inflammatory bowel disease in the province of Manitoba." (Co-investigator: James F. Blanchard, M.D., PhD.) $123,000
7. Manitoba Medical Services Foundation (1996). Principal investigator "Inflammatory bowel disease and the 2 integrin adhesion pathway: Broadening immunopathogenetic concepts and seeking specific therapeutic targets." $20,000
8. Health Sciences Centre Research Foundation (1996). Principal investigator. "Beta-2 integrin/ICAM adhesion pathway in inflammatory bowel disease: A longitudinal study." $45,000
9. Dr. Paul H.T. Thorlakson Foundation Fund (1996). Principal investigator. "Beta-2 integrin/ICAM adhesion pathway in inflammatory bowel disease: A longitudinal study."
$5,000
10. Jouveinal + Axcan Pharma (1997-1998). Principal investigator. "Impact of gastroenterology consultation on health care utilization and patient outcomes in functional abdominal disorders." (Co-investigator: Alexandra Ilnyckyj, M.D.). $80,000
11. Crohn's and Colitis Foundation of Canada (1997-1999). Principal investigator. "The requirements of health care services by patients with inflammatory bowel disease in the province of Manitoba: A population-based study." (Co-investigator: James F. Blanchard, M.D., PhD.) $100,000
12. Abbott Laboratories Inc. (1998-1999). Principal investigator. Lansoprazole in the treatment of chronic laryngitis secondary to gastroesophageal reflux. (Co-investigator: Lesley Z. Garber, M.D.) $30,000
13. Medical Research Council of Canada (1999-2002, MT-15537). Co-principal investigator. Viruses and Crohn’s disease: A population-based case control study. (Co-PI: James F. Blanchard, M.D., Ph.D.) $148,000
14. Manitoba Medical Services Foundation Dr. F. W. Du Val Clinical Research Professorship Award (1999-2002). $150,000
15. Crohn’s and Colitis Foundation of Canada (2000-2003). Principal investigator. Mycobacterium paratuberculosis and other microbes in Crohn’s disease. (Co-investigators: James F. Blanchard, M.D., Ph.D., David Relman, MD, Gopi Nayar, DVM) $180,000
16. Astra Canada Inc (2000-2002). Principal investigator. Gastrointestinal symptoms and Helicobacter pylori infection in Wasagamack. (Co-investigators: Bruce Martin, MD, Pam Orr, MD) $200,000
17. Health Sciences Centre Research Foundation (2000-2001). Principal investigator. Assessing the burden of illness of inflammatory bowel disease in Manitoba. (Co-investigator: James F. Blanchard, M.D., Ph.D.) $25,000
18. Crohn’s and Colitis Foundation of Canada Research Scientist Award-Canadian Institute of Health Research Industry Salary Support Program (2001-2005) “Pursuing the etiologies of the inflammatory bowel diseases.” $375,000
19. Canadian Institute of Health Research Investigator Award (2001-2006) “Pursuing the etiologies of the inflammatory bowel diseases.” $385,000
20. Health Sciences Centre Research Foundation (2001-2002). “Comparison of cortical activation from visceral versus somatic painful stimuli in irritable bowel syndrome.” (Co-investigator: Michael McIntyre, Ph.D.) $25,000
21. Canadian Association of Gastroenterology/ Abbott Laboratories Fellowship (2002-2003). Awarded to Michael Cantor, MD (C. Bernstein, supervisor). “Cytokine genotyping in inflammatory bowel disease.” $50,000
22. Canadian Institute of Health Research (2002-2007) “Understanding the biological, clinical, and psychosocial determinants of health outcomes in inflammatory bowel disease: A research program.” (Co-investigators: James F. Blanchard, M.D., Ph.D., Phillip Jacobs, Ph.D., Lesley Graff, Ph.D., John Walker, Ph.D., Tom Hazzard, Ph.D., William J Leslie, MD, Donald Houston, MD) $1,200,000
23. NSERC/CHRP (2002-2005) "An interdisciplinary non-invasive infrared test for colorectal cancer." (PI: Ian Smith, PhD, National Research Centre Institute for Biodiagnostics, co-investigator, Charles N. Bernstein). $330,000
24. Health Sciences Centre Research Foundation Innovations and Opportunities Fund (2002-2003). “Nutritional intake of adults with inflammatory bowel disease.” (Co-PI: Savita Bector, MSc, RD) $25,000
25. Canadian Association of Gastroenterology-Canadian Digestive Health Foundation/Astra Zeneca fellowship. Awarded to Teresa Longobardi. (C. Bernstein, supervisor). 2003-2005. “Economics of IBD- Utilization and cost of medical care due to inflammatory bowel disease in Manitoba.” $90,000
26. Crohn’s and Colitis Foundation of Canada (2003-2004). “The Burden of IBD in Canada.” (Co-investigators: James F. Blanchard, MD, Ph.D., Teresa Longobardi, Ph.D., Phillip Jacobs, Ph.D., David Israels, MD, and Richard Fedorak, MD) $200,000
27. Organ Imaging Fund, Department of Radiology, Health Sciences Centre, Winnipeg, Manitoba (2003-2004). “A prospective comparison study of MRI versus small bowel follow through in recurrent Crohn’s disease.” $9000.
28. Crohn’s and Colitis Foundation of Canada (2004-2007). “Mucosal associated microflora and the development of Crohn’s disease”. (co-PI: Denis Krause, PhD, University of Manitoba) $305,000.
29. Canadian Institutes of Health Research (2004-2005). “Evaluation of advanced spectroscopic methods for the diagnosis of colorectal cancer”. (co-PI: Ian C Smith, PhD, NRC). $93000.
30. Crohn’s and Colitis Foundation of Canada (2005-2007). “A population-based characterization of potential microbial etiologies of IBD using geographically defined high and low rate prevalence/incidence areas in Manitoba”. (co-investigators: Chris Green, PhD, Manitoba Health and Susan Springthorpe, PhD, and Syed Sattar, PhD University of Ottawa, and James F. Blanchard, MD, Ph.D., University of Manitoba) $200,000.
31. Thorlakson Foundation (2006-2007). “Long term use of Statins and Colorectal Cancer Risk: A Population-Based Cohort Study.” (Principle Investigator= H Singh, co-investigators= Donna Turner, Anita Kozyrskyj, Sala Mahmud, Charles Bernstein, University of Manitoba.) Grant: $35,663.
32. Crohn’s and Colitis Foundation of Canada Research Scientist Award (2006-2011) “IBD: Defining the burden, finding the cause, and enhancing diagnosis and treatment.” $375,000.
33. Manitoba Medical Services Foundation (2007). “Risk of cervical cytological abnormalities and cervical cancer among women with IBD: A population based case-control study”. (Principle Investigator= H Singh, co-investigators= Charles Bernstein, Alain Demers, Sala Mahmud, Erich Kliewer, University of Manitoba.) Grant: $35,163.
34. Manitoba Medical Services Foundation (2007). “Homocysteinemia and B vitamin status in inflammatory bowel disease: Is there an association to disease activity?” (Principle Investigator= K Vagianos, co-investigators= Charles Bernstein, Grant: $40,000.
35. Crohn’s and Colitis Foundation of Canada Innovations in IBD competition (2007). "Prevalence of the Uncultured Bacterial Candidate Phylum, TM7, in IBD Biopsy Tissue". (Co-principle investigator, Denis Krause): $49,000.
36. Canadian Institutes of Health Research (2007-2010). “Comparing rheumatoid arthritis and inflammatory bowel disease by serology, gene studies, and ethnicity: Using commonalities and differences to develop etiologic hypotheses” (AIBD Study). (Co-investigators, Hani El-Gabalawy, Brenda Elias, Mark Silverberg, Xikui Wang). $975000.
37. Crohn’s and Colitis Foundation of Canada (2007-2010). “Role of Bacteroides spp. and Escherichia coli in inflammatory bowel disease”. (Principle Investigator= Denis Krause, Co-investigator=Charles Bernstein): $439,934.
INDUSTRY-SPONSORED THERAPY STUDIES
1. The treatment of IBD with oral Pentasa (mesalamine): Compassionate Program. Marion Merrell Dow. UCLA. Co-investigator. 1991-1993.
2. Safety and efficacy of Zileuton versus placebo for eight weeks in patients with active ulcerative colitis. Abbott Laboratories. UCLA. Co-investigator. 1992-1993.
3. Long term safety and efficacy of placebo controlled Zileuton in patients with ulcerative colitis in remission. Abbott Laboratories. UCLA. Co-investigator. 1992-1993.
4. A 42-day, double-blind, parallel group, multicenter study to compare the safety and efficacy of three dose levels of Budesonide with placebo in adult patients with distal UC/proctitis. Astra Draco. UCLA. Co-investigator. 1992-1993.
5. A randomized trial to compare the efficacy and safety of Welferon and Intron A for the treatment of chronic hepatitis C. Burroughs Wellcome. University of Manitoba. Co- investigator. 1994.
6. A phase III randomized double-blind controlled trial of recombinant methionyl-interferon consensus (r-met/INF-Con) in patients with chronic hepatitis C virus (HCV) infection. Amgen. University of Manitoba. Co-investigator. 1994.
7. A multicenter randomized double-blind placebo controlled study to assess the safety and efficacy of oral famcyclovir for the treatment of chronic hepatitis B. Smith Kline Beecham. University of Manitoba. Co-investigator. 1994.
8. Efficacy and safety of Deflazacort compared to prednisone in the treatment of actute Crohn's disease. Nordic Merrell Dow. University of Manitoba. Centre principal nvestigator. 1994.
9. Treatment of Helicobacter pylori in peptic ulcer disease. Astra Canada. University of Manitoba. Centre principal investigator.1994.
10. A multicentre evaluation of the efficacy of Methotrexate in chronically active Crohn's disease. Medical Research Council of Canada. University of Manitoba. Centre principal investigator. 1995-1997.
11. Interleukin-10 in the treatment of chronic active Crohn's disease. Schering Canada Inc. University of Manitoba. Centre principal investigator. 1996-1997.
12. Short chain fatty acids in the treatment of chronic radiation proctitis. Orphan Medical Inc. University of Manitoba. Centre principal investigator. 1996-1997.
13. Synsorb Cd in the treatment of relapsing Clostridium difficile colitis.Synsorb Inc. University of Manitoba. Centre principal investigator. 1997-1999.
14. A double blind placebo controlled trial to evaluate the efficacy and safety of R108512 tablets in subjects with chronic constipation. Janssen Pharmaceutica. University of Manitoba. Centre principal investigator. 1998-1999.
15. A double blind, placebo-controlled trial to assess the safety and efficacy of anti-TNF- antibody, CDP571 in treating patients with moderate to severe Crohn's Disease. Celltech Therapeutics. University of Manitoba. Centre principal investigator. 1998-2000.
16. A double blind, placebo-controlled trial of budesonide plus antibiotics in the treatment of Crohn's disease. Astra Canada and CCFC. University of Manitoba. Centre principal investigator. 1998-2000.
17. A 12 week randomized double blind dose ranging placebo controlled study of Alosetron in subjects with non-ulcer dyspepsia. Glaxo Wellcome. University of Manitoba. Centre principal investigator. 1999-2000.
18. Double blind placebo controlled randomized multi centered parallel group dose ranging study to investigate the efficacy and safety of Cilansetron in non constipated patients with irritable bowel syndrome. Solvay. University of Manitoba. Centre principal investigator. 1999-2000.
19. A randomized double-blind placebo controlled trial of TNF- chimeric monoclonal antibody (Infliximab, Remicade) in the long term treatment of patients with moderately to severely active Crohn’s disease. Centocor Inc. University of Manitoba. Centre principal investigator. 1999-2000.
20. A double blind placebo controlled randomized multi centred study to investigate the safety and efficacy of 2 mg Cilansetron in non constipated subjects with established irritable bowel syndrome. Solvay. University of Manitoba. Centre principal investigator. 2000.
21. A randomized double-blind placebo controlled trial of TNF- chimeric monoclonal antibody (Infliximab, Remicade) in the long term treatment of patients with fistulizing Crohn’s disease. Centocor Inc. University of Manitoba. Centre principal investigator. 2000-2001.
22. LDP-02. A phase II, randomized, placebo-controlled, double blind, parallel group study to determine the safety, pharmacokinetics and effectiveness of LDP-02 in patients with mildly to moderately active Crohn’s disease. Leukosite. University of Manitoba. Centre principal investigator. 2000-2001.
23. A randomized, double masked, placebo-controlled study of subcutaneously administered recombinant human interleukin-11 (IL-11) in patients with active Crohn’s disease on or off concomitant systemic corticosteroid treatment. Wyeth-Ayerst. University of Manitoba. Centre principal investigator. 2000-2001.
24. A phase III, multicentre, randomized, placebo-controlled, double-blind, parallel-group clinical trial to confirm the efficacy and safety of Synsorb Cd (16 g/day or 24 g/day) for the treatment of recurrent Clostridium difficile associated disease (RCDAD). Synsorb Biotech. University of Manitoba. Centre principal investigator. 2000-2001.
25. LDP-02. A phase II, randomized, placebo-controlled, double blind, parallel group multi-center study to determine the safety, pharmacokinetics and effectiveness of LDP-02 in patients with mildly to moderately active ulcerative colitis. Millenium Pharmaceuticals Inc. University of Manitoba. Centre principal investigator. 2000-2001.
26. A phase III multinational, multisite, double blind, placebo-controlled parallel group 28 week study to assess the efficacy and safety of the engineered human anti-TNF- antibody, CDP571 to prevent disease flare whilst allowing steroid withdrawal in steroid dependent patients with Crohn’s disease following an intravenous dose of 10 mg/kg CDP-571 given at 8 weekly intervals. Celltech Therapeutics. University of Manitoba. Centre principal investigator. 2000-2002.
27. A phase III multinational, multisite, open label 32 week long term follow up study to assess the safety and efficacy of the engineered human anti-TNF- antibody, CDP571 to in patients with Crohn’s disease. Celltech Therapeutics. University of Manitoba. Centre principal investigator. 2000-2002.
28. A phase III multinational, multisite, double blind 28 week study to assess the safety and efficacy of the engineered human anti-TNF- antibody, CDP571 in patients with active Crohn’s disease. Celltech Therapeutics. University of Manitoba. Centre principal investigator. 2001-2002.
29. A double-blind, placebo-controlled, randomized, multinational study to investigate the safety and efficacy of 2 mg TID of Cilansetron over 26 weeks in diarrhea-predominant irritable bowel syndrome. Solvay Pharmaceuticals, University of Manitoba. Centre principal investigator. 2002-2003.
30. A randomised, double-blind, placebo-controlled, four parallel groups, dose finding study of BIRB 796 BS (10, 20, and 30 mg) administered twice a day orally over 8 weeks in patients with moderate to severe Crohn's disease followed by a 18 weeks treatment extension in patients with clinical remission or clinical response after 8 weeks treatment with the respective dose of BIRB 796 BS. Boehringer Ingelheim (Canada) Ltd. University of Manitoba. Centre principal investigator. 2002-2003.
31. A phase III, international, multicenter, double-blind, placebo-controlled study of the safety, efficacy and tolerability of intravenous Antegren (tm) (Natalizumab) in subjects with moderately to severely active Crohn’s disease. Elan Pharmaceuticals, Inc. University of Manitoba. Centre principal investigator. 2002-2003.
32. A phase III, international, multicenter, double-blind, placebo-controlled study of the efficacy, safety and tolerability of intravenous Antegren (tm) (Natalizumab) (300 mg Monthly) in maintaining clinical response and remission in subjects with Crohn's disease. Elan Pharmaceuticals, Inc. University of Manitoba. Centre principal investigator. 2002-2003.
33. A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren ™ (natalizumab) in Crohn’s Disease Subjects Subjects Who Have previously Participated in Studies CD251, CD301, CD303, or CD306. Protocol CD351. Elan Pharmaceuticals, Inc. University of Manitoba. Centre principal investigator. 2002-2004.
34. A randomized, double blind, placebo-controlled trial of Ciprofloxacin or Metronidazole for the treatment of Crohn's disease perianal fistulas. CCFA. University of Manitoba. Centre principal investigator. 2002-2003.
35. A phase II, double-blind, placebo-controlled study to determine the safety and efficacy of a humanized anti-interferon monoclonal antibody (HuZAF) administered to patients with moderate to severe Crohn's Disease. Protein Design Labs. University of Manitoba. Centre principal investigator. 2002-2003.
36. A phase III randomized, placebo-controlled, double-blind, parallel group, multicenter study to assess the efficacy and safety of Omega-3 Fatty Acids (Epanova ) for the maintenance of sypmtomatic remissionin subjects with Crohn's disease (CD).
EPIC-2. University of Manitoba. Centre principal investigator. 2003-2004.
37. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients with Active Crohn’s Disease. Wyeth-Ayerst Research. University of Manitoba. Centre principal investigator. 2002- 2003.
38. A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with Active Ulcerative Colitis (Protocol C0168T46). Centocor, Inc. University of Manitoba. Centre principal investigator. 2003- 2004.
39. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging
Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) in Patients
With Mild to Moderate Ulcerative Colitis. Wyeth-Ayerst Research. University of
Manitoba. Centre principal investigator. 2003 -2004.
40. A One Year, Multi-Center, Randomised, Double-Blind Placebo-Controlled Parallel-
Groups Assessment of the Tolerability, Safety and Efficacy of Epanova Soft Gelatin Capsules 4g/day for Maintenance of Remission of Crohn's Disease (CD) Tillott’s No.: TP0307. Tillotts Pharma AG. University of Manitoba. Centre principal investigator. 2004 -2005.
41. Randomized, Stratified, Double-blind, Placebo-controlled Phase 2 Study of the Steroid-
sparing Properties of sargramostim ( LEUKINE) Therapy in Patients With
Corticosteroid-dependent Crohn’s Disease. Protocol 307501. Berlex Laboratories.
University of Manitoba. Centre principal investigator. 2004 -2005.
42. Open-label Trial of LEUKINE (sargramostim), a Recombinant Human Granulocyte-
Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn’s Disease. Protocol 307340. Berlex Laboratories. University of Manitoba. Centre principal investigator. 2004-2005.
43. Clinical protocol for a randomized, placebo-controlled, double-blind, multicenter study to determine the efficacy and safety of VSL#3 probiotic food supplement mixture in prevention of endoscopic recurrence of Crohn's disease after ileo-colonic surgical resection and small-intestine-to-colon anastomosis. University of Manitoba. Centre principal investigator. 2004-2005.
44. A Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Human Anti TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Crohn's Disease - M02-404. Abbott Laboratories, Limited University of Manitoba. Centre principal investigator. 2003-2005.
45. A phase III randomized, placebo-controlled, double-blind, parallel group, multicenter study to assess the efficacy and safety of Omega-3 Fatty Acids (Epanova ) for the maintenance of sypmtomatic remissionin subjects with Crohn's disease (CD) - TP0308.Tillotts Pharma AG. University of Manitoba. Centre principal investigator. 2004-2005.
46. A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects with Moderately Active Crohn’s Disease. Protocol CL0600-008. NPS Pharmaceuticals, Inc. University of Manitoba. Centre principal investigator. 2004 – 2006.
47. An Open Label Extension Study of the Safety and Efficacy of ALX-0600 inm Subjects with Crohn’s Disease Who Completed the Pilot Study Protocol CL0600-008. Protocol CL0600-009. NPS Pharmaceuticals, Inc. University of Manitoba. Centre principal investigator. 2004-2006.
48. A 12-Months, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Proof of Concept Study of the Efficacy of Oral RAD001 (6 mg/day) versus Azathioprine and Placebo in Crohn’s Disease. CRAD001F2201. Novartis Pharmaceuticals Canada Inc. University of Manitoba. Centre principal investigator. 2004-2006.
49. A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous AntegrenTM (natalizumab) in Subjects with Moderately to Severely Active Crohn’s Disease with Elevated C-Reactive Protein. ELN100226-CD307. Elan Pharmaceuticals Inc. University of Manitoba. Centre principal investigator. 2004-2006.
50. A Phase 3, Multicenter, Randomized, Double-blind, Parellel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25 mg QD and 50 Mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. Protocol # 197-02-220. Otsuka Maryland Research Institute. University of Manitoba. Centre principal investigator. 2004-2007.
51. A Phase III multi-national, multi-centre, double-blind placebo-controlled parallel group, 26 week study to assess the maintenance of clinical response to humanized anti-TNF PEG conjugate, CDP870 400 mg sc, (dosed 4-weekly from Weeks 8-24), in the treatment of patients with active Crohn’s disease who have responded to open induction therapy (dosed at Weeks 0, 2 and 4) with CDP870. Protocol # CDP870-032. Celltech R & D Limited. University of Manitoba. Centre principal investigator. 2004-2006.
52. A Phase III multi-national, multi-centre, open label, 52 week safety study to assess the safety of chronic therapy with humanized anti-TNF PEG conjugate, CDP870 400 mg sc, (dosed 4-weekly to Week 48), in the treatment of patients with active Crohn’s disease who previously completed studies CDP870-031 or CDP870-032 – Protocol # CDP870-033. Celltech R & D Limited. University of Manitoba. Centre principal investigator. 2004-2006.
53. A Phase III multi-national, multi-centre, open label, 52 week safety study to assess the safety of re-exposure after a variable interval and subsequent chronic therapy with humanized anti-TNF PEG conjugate, CDP870 400 mg sc, (dosed at weeks 0, 2 and 4 then 4-weekly to Week 48), in the treatment of patients with active Crohn’s disease who previously been withdrawn from studies CDP870-031 or CDP870-032 due to an exacerbation of Crohn’s disease. Protocol # CDP870-034. Celltech R & D Limited. University of Manitoba. Centre principal investigator. 2004-2006.
54. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parellel-Arm, Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects with Active Ulcerative Colitis. Protocol # 197-02-218. Otsuka Maryland Research Institute. University of Manitoba. Centre principal investigator. 2004-2007.
55. A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn’s Disease M04-690. (Phase 3) Abbott Laboratories Ltd. University of Manitoba. Centre principal investigator. 2004-2006.
56. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderate to Severe Crohn’s Disease who Have Lost Response or are Intolerant to Infliximab M04-691. (Phase 3) Abbott Laboratories Ltd. University of Manitoba. Centre principal investigator. 2004-2006.
57. A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren(tm) (natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren(tm) Crohn's Disease Studies ELN100226-CD351. Elan Pharmaceuticals Inc. University of Manitoba. Centre principal investigator. 2003-2006.
58. A Phase 3, Multicenter, 52-week, Open-label, Extension Study of the Safety and Efficacy of 25 mg or 50 mg of OPC-6535 Oral Tablets in the Treatment of Subjects with Ulcerative Colitis. Protocol 197-02-219. Otsuka Maryland Research Institute. University of Manitoba. Centre principal investigator. 2005-2007.
59. A Multicenter, Randomized, Blinded, Placebo-controlled, Phase IIa Study of Human Monoclonal Antibody to IL-12p40 (CNTO1275) in Subjects With Crohn’s Disease Inadequately Controlled by 5-Aminosalicylates and/or Corticosteroids, and Open-label Administration in Subjects Who are Nonresponders to Anti-TNFα Therapy (C0379T07) Centocor, Inc. University of Manitoba. Centre principal investigator. 2005-2007.
60. A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole in Patients with C. Difficile-Associated Diarrhea Protocol # GD3-170-301. Genzyme Corporation. University of Manitoba. Centre principal investigator. 2005 –2007
61. Phase 3 Randomized, Double-Blind, Placebo-Controlled Induction Study of Sargramostim (Leukine®) in Patients with Active Crohn’s Disease. Berlex protocol: 308380. Berlex Canada Inc. University of Manitoba. Centre principal investigator. 2005-2007.
62. A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of itopride HCL in patients suffering from functional dyspepsia. ITOFD04-03. Axcan Pharma. University of Manitoba. Centre sub-investigator. 2005-2007.
63. A multicentre, open-label study to evaluate the long-term safety and efficacy of itopride HCl in patients suffering from functional dyspepsia. ITOFD04-04. Axcan Pharma. University of Manitoba. Centre sub-investigator. 2005-2007.
64. A Phase 2, Randomized, Double-blind, Multicenter, Dose Exploration Study of Visilizumab in Subjects with Intravenous Steroid Refractory Ulcerative Colitis Protocol Number 291-418. PDL BioPharma Inc. University of Manitoba. Centre principal investigator. 2006-2009.
65. A Randomized, Double-Blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study Protocol 291-417. PDL BioPharma Inc. University of Manitoba. Centre principal investigator. 2006-2009.
66. An Observational Follow-up Study for Subjects Receiving Salvage Therapy After
Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory
Ulcerative Colitis Protocol Number 291-420. PDL BioPharma Inc. University of
Manitoba. Centre principal investigator. 2006-2009.
67. A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety
Evaluation of Inflabloc Cap in the Treatment of Patients with Moderately active
Crohn’s Disease. Protocol Number CL-C002-00. Inflabloc Pharmaceuticals, Inc.
University of Manitoba. Centre principal investigator. 2006 – 2007.
68. A Double-blind, Randomized, Placebo-controlled Multicenter Study to Assess the
Safety and Efficacy of AST-120 in Mild to Moderately Active Crohn’s Patients with
Fistulas. Protocol Number AST001.Ocera Therapeutics, Inc. University of Manitoba
Centre principal investigator. 2006 – 2008.
69. Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux
Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg
o.d. Over 8 Weeks The“ Real-Life“ Study BY1023/ M3-341 ALTANA Pharma.
Centre. University of Manitoba Centre sub-investigator. 2006 – 2007.
70. C87059 A Phase IIIb multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease (COSPAR I). UCB SA. Health Sciences Centre Centre principal investigator. 2006 - 2008
71. An open-label, multi-center trial to examine the long term safety, efficacy, and
corticosteroid-sparing effect of certolizumab pegol in patients with moderate to
severe Crohn's disease who have failed tapering of corticosteroids, needed
corticosteroids after completion of tapering, or have successfully completed the trial
C87059 (COSPAR I). C87065 (COSPAR II). UCB. Health Sciences Centre. Centre
principal investigator. 2007 – 2008
72. A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the
Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept
in Subjects with Active Crohn’s Disease (CD) who have an Inadequate Clinical
Response and/or Intolerance to Medical Therapy. Bristol-Myers Squibb. Health
Sciences Centre. Centre principal investigator. 2007-2009
73. Protocol W06-405 A Multicenter, Open-Label, Treatment Protocol of the Human
Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects with Moderate
to Severe Crohn’s Disease (ACCESS) Abbott Laboratories. Health Sciences Centre.
Centre sub-investigator. 2007-2008
74. Protocol M06-826: A Multicenter, Randomized, Double-blind, Placebo Controlled
Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction
of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative
Colitis. Abbott Laboratories. Health Sciences Centre. Centre sub-investigator. 2007 -
2009.
75. A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel
Group Study of Renzapride in Women with Constipation-Predominant Irritable
Bowel Disease (C-IBS) Protocol ATL1251/038/CL. Alizyme Therapeutics. Health
Sciences Centre. Centre principal investigator. 2007-2008
76. Protocol GD3-170-302 A Phase III. A Randomized, Double-Blind Study of GT267-
004 Versus Vancomycin, and GT267-004 Versus Metronidazole, in Patients with C.
Difficile-Associated Diarrhea. Genzyme Corporation. Health Sciences Centre.
Centre principal investigator. 2007 - 2008
77. A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study to Determine the
Safety, Tolerability, pharmacokinetics, and Pharmacodynamics of MLN0002
Following Multiple Intravenous Doses in Patients with Ulcerative Colitis.
Millennium Pharmaceuticals. Health Sciences Centre. Centre principal investigator.
2007-2009
PUBLICATIONS
(manuscripts where CN Bernstein does not appear as first author, but is otherwise the corresponding author are denoted with *)
A. PEER-REVIEWED
Original Research
1. Minuk GY, German G, Bernstein C, Benarroch A, Gauthier T, Sekla L. A pilot study of steroid withdrawal followed by oral acyclovir in the treatment of chronic type B hepatitis. Clinical and Investigative Medicine 1992; 15: 506-12.
2. Bernstein CN, Robert ME, Eysselein VE Colonic mucosal substance P levels are increased in ulcerative colitis but not in Crohn's disease. American Journal of Gastroenterology 1993: 88; 908-913.
3. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994: 343; 71-74.
4. Bernstein CN, Ament ME, Ridgeway MJ, Artinian L, Shanahan F. Milk tolerance in adults with ulcerative colitis. American Journal of Gastroenterology 1994; 89: 872-877.
5. Bernstein CN, Artinian L, Anton PA, Shanahan F. Low dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematological toxicity. Digestive Diseases and Science.1994; 39: 1638-1641.
6. Bernstein CN, Vidrich A. Isolation, identification and culture of normal mouse colonic glial cells. Glia 1994;12: 108-116.
7. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. Journal of Bone and Mineral Research 1995: 10; 250-256.
8. Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: A prospective study. Gastrointestinal Endoscopy 1995; 42: 232-237.
9. Bernstein CN, Weinstein WM, Levine DS, Shanahan F. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. American Journal of Gastroenterology 1995: 90; 2106-2114.
10. Bezabeh T, Smith ICP, Krupnik E, Somorjai RL, Kitchen DG, Bernstein CN, Pettigrew NM, Bird RP, Lewin KJ, Briere KM. Diagnostic potential for cancer via 1H magnetic resonance spectroscopy of colon tissue. Anticancer Research 1996:16; 1553-1558.
11. Bernstein CN, Pettigrew NM, El-Gabalawy HS, Sargent M, Meu Y, Wilkins J. The differential expression of a novel intestinal epithelial glycoprotein in various forms of inflammatory bowel disease. American Journal of Clinical Pathology 1996; 106: 42-51.
12. Bernstein CN, Niazi N, Robert M, Mertz H, Kodner A, Munakata J, Mayer EA. Rectal afferent function in patients with inflammatory and functional intestinal disorders. Pain 1996; 66: 151-162.
13. Bernstein CN, Sargent M, Gallatin WM, Wilkins J. 2 integrin/ICAM expression
in the normal human intestine. Clinical and Experimental Immunology1996; 106: 160-169.
14. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: A pilot study. Alimentary Pharmacology and Therapeutics 1996;10: 777-786.
15. Bernstein CN, Rollandelli R, Niazi N, Robert M, Kodner A, Hirsch T, Mayer EA. Characterization of afferent mechanisms in ileo-anal pouches. American Journal of Gastroenterology 1997; 92: 103-108.
16. *Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112: 1854-1858.
17. Bernstein CN, Boult IF, Greenberg HM, van der Putten W, Duffy G, Grahame GR. A prospective randomized comparison between small bowel enteroclysis and small bowel follow-through in Crohn's disease. Gastroenterology 1997; 113: 390-398.
18. El-Gabalawy H, King R, Bernstein C, Ma G, Mou Y, Alguacil-Garcia A, Fritzler M, Wilkins J. Expression of N-acetyl-D-galactosamine associated epitope in synovium: A potential marker of glycoprotein production. Journal of Rheumatology 1997; 24: 1355-63.
19. *Patel Y, Pettigrew NM, Grahame GR, Bernstein CN. The diagnostic yield of lower endoscopy plus biopsy in nonbloody diarrhea. Gastrointestinal Endoscopy 1997; 46: 338-343.
20. Bernstein CN, Sargent M, Rawsthorne P, Rector E. Peripheral blood lymphocyte 2 integrin and ICAM expression in inflammatory bowel disease. Digestive Diseases and Sciences 1997; 42: 2338-2349.
21 Bernstein CN, Sargent M, Gallatin WM. 2 integrin/ICAM expression in Crohn's disease. Clinical Immunology and Immunopathology 1998; 86: 147-159.
22. *Embil JM, Choudhri SH, Smart G, Aldor T, Pettigrew NM, Grahame GR, Dawood MR, Bernstein CN. Comparison of salivary and serum enzyme immunoassays for the diagnosis of Helicobacter pylori infection. Canadian Journal of Infectious Diseases 1998: 9: 277-280.
23. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. The epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: A population-based study. American Journal of Epidemiology 1999; 149: 916-924.
24. Bernstein CN, Mckeown I, Embil JM, Blanchard JF, Dawood M, Kabani A, Kliewer E, Smart G, Coghlan G, Macdonald S, Cook C, Orr P. Seroprevalence of Helicobacter pylori, and incidence of gastric cancer and peptic ulcer associated hospitalizations, in a Canadian Indian population. Digestive Diseases and Sciences 1999; 44: 668-674.
25. *Loudon CP, Corroll V, Butcher J, Rawsthorne P, Bernstein CN. The effects of physical exercise on patients with Crohn's disease. American Journal of Gastroenterology 1999; 94: 697-703.
26. *Rawsthorne P, Shanahan F, Cronin NC, Anton PA, Löfberg R, Bohman L, Bernstein CN. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. American Journal of Gastroenterology 1999; 94: 1298-1303.
27. *McKeown I, Orr P, Macdonald S, Kabani A, Brown R, Coghlan G, Dawood M, Embil J, Sargent M, Smart G, Bernstein CN. Helicobacter pylori in the Canadian arctic: seroprevalence and detection in community water samples. American Journal of Gastroenterology 1999;94: 1823-1829.
28. *Ilnyckyj A, Blanchard JF, Rawsthorne P, Bernstein CN. Perianal Crohn’s disease and pregnancy: Role of the mode of delivery. American Journal of Gastroenterology 1999; 94: 3274-3278.
38. Bernstein CN, Papineau N, Rawsthorne P, Zajakowski J, Ogrusko G, Blanchard JF. The direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. American Journal of Gastroenterology 2000; 95: 677-683.
30. Chang L, Munakata J, Mayer EA, Schmulson MJ, Johnson TD, Bernstein CN, Saba
L, Naliboff B, Anton PA, Matin K. Perceptual responses in patients with inflammatory and functional bowel disease. Gut 2000; 47: 497-505.
31. Pimental M, Roberts D, Bernstein CN, Hoppensack M and Duerksen DR.
Clinically significant gastrointestinal bleeding in critically ill patients in an era
of stress prophylaxis. American Journal of Gastroenterology 2000; 95: 2801-2806.
32. Bernstein CN, Blanchard JF, Leslie WD, Wajda A, Yu N. The incidence of fractures among patients with IBD: A population-based study. Annals of Internal Medicine 2000; 133: 795-799.
33. *Bezabeh T, Somorjai RL, Smith ICP, Nikulin AE, Dolenko B, Bernstein CN. The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: Distinguishing ulcerative colitis from Crohn’s disease. American Journal of Gastroenterology 2001; 96: 442-448.
34. Bernstein CN, Blanchard JF, Houston D, Wajda A. The incidence of venous thromboembolic disease among patients with IBD: A population-based study. Thrombosis and Haemostasis 2001; 85: 430-434.
35. Bernstein CN, Kliewer E, Wajda A, Blanchard JF. The incidence of cancer among patients with IBD: A population-based study. Cancer 2001; 91: 854-862.
36. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. American Journal of Gastroenterology 2001; 96: 1116-1122.
37. Bernstein CN, Kraut A, Blanchard JF, Rawsthorne P, Yu N, Walld R. The relationship between inflammatory bowel disease and socioeconomic variables. American Journal of Gastroenterology 2001; 96: 2117-2125.
38. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambeault A, Bernstein CN, Novak C, Heath PK, Targan SR for the CDP-571 Crohn’s Disease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn’s disease: A randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120: 1330-1338.
39. Bernstein CN, Orr K, Blanchard JF, Sargent M, Workman D. The development of an assay for antibodies to Saccharomyces cerevisiae: Easy, cheap and specific for Crohn’s disease. Canadian Journal of Gastroenterology 2001; 15: 499-504.
40. Blanchard JF, Bernstein CN, Wajda A, Rawsthorne P. Small area variations
socio-demographic correlates for the incidence of Crohn's disease and ulcerative colitis. American Journal of Epidemiology 2001; 154: 328-35.
41. *Fallows G, Rubinger M, Bernstein CN. Does gastroenterology consultation change management of patients receiving hematopoietic stem cell transplantation? Bone Marrow Transplantation 2001; 28: 289-294.
42. *Metge CJ, Blanchard JF, Peterson S, Bernstein CN. Use of pharmaceuticals by IBD patients: A Population-based study. American Journal of Gastroenterology 2001;96: 3348-3355.
43. Hayden CW, Bernstein CN, Hall RA, Vakil N, Garewal HS, Fass R. The usage of supplemental alternative medicine by community-based patients with gastroesophageal reflux disease (GERD). Digestive Diseases and Sciences 2001; 47: 1-8.
44. Bernstein CN, Frankenstein UN, Rawsthorne P, Pitz M, Summers R, McIntyre MC. Cortical mapping of visceral pain in patients with gastrointestinal disorders using functional magnetic resonance imaging. American Journal of Gastroenterology 2002; 97: 2; 319-27.
45. *Faybush E, Blanchard JF, Rawsthorne P, Bernstein CN. Generational differences in the age at diagnosis with IBD: Genetic anticipation, bias or temporal effects. American Journal of Gastroenterology 2002; 97: 636-40.
46. *Sinha SK, Martin B, Sargent M, McConnell JP, Bernstein CN. Age at acquisition of Helicobacter pylori in a paediatric Canadian First Nations population. Helicobacter 2002; 7: 76-85.
47. Bernstein CN, Sargent M, Rector E. Alteration in expression of beta-2 integrins on lamina propria lymphocytes in ulcerative colitis and Crohn’s disease. Clinical Immunology 2002; 104: 67-72.
48. Ilnyckyj A, Bernstein CN. Sexual abuse in irritable bowel syndrome: To ask or not to ask, that is the question. Canadian Journal of Gastroenterology 2002; 16: 801-806.
49. Tkachuk, G., Graff, L, Martin,G. Bernstein CN. Controlled trial of cognitive behavioral group treatment for irritable bowel syndrome in a medical setting. Journal of Clinical Psychology in Medical Settings 2003; 10: 57-69.
50. *Longobardi T, Jacobs P, Wu L, Bernstein CN. Work losses related to inflammatory bowel disease in Canada: Results from a National Population Health Survey. American Journal of Gastroenterology 2003; 98: 844-9.
51. Bernstein CN, Leslie WD, Taback S. Bone density in a population based cohort of premenopausal adult women with early-onset inflammatory bowel disease. American Journal of Gastroenterology 2003; 98:1094-100.
52. *Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: Results from the National Health Interview Survey. American Journal of Gastroenterology 2003; 98:1064-1072.
53. Ilnyckyj A, Graff L, Blanchard JF, Bernstein CN. Therapeutic value of a gastroenterology consultation in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2003;17: 871-80.
54. Bernstein CN, Metge C, Blanchard JF, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. American Journal of Gastroenterology 2003; 98: 1797-1801.
55. Targownik, LE, Gralnek IM, Dulai GS, Spiegel BMR, Oei T, Bernstein CN.
Management of acute non-variceal upper gastrointestinal hemorrhage: Comparison of a U.S. and a Canadian medical center. Canadian Journal of Gastroenterology 2003; 17: 489-95.
56. Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. American Journal of Gastroenterology 2003; 98: 2468-2473.
57. Minuk GY, Zhang M, Wong SGM, Uhanova J, Bernstein CN, Martin B, Dawood MR, Vardy L, Giulvi A. Viral hepatitis in an isolated Canadian First Nations community. Canadian Journal of Gastroenterology 2003:17: 593-596.
58. Bernstein CN, Nayar G, Hamel A, Blanchard JF. A pursuit of animal borne infections in the mucosa of subjects with inflammatory bowel disease and population-based controls. Journal of Clinical Microbiology 2003; 41:4986-90.
59. Bernstein CN, Metge C, Blanchard JF, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? American Journal of Gastroenterology 2003; 98: 2784-2788.
60. Zhang M, Uhanova J, Corbin I, Bernstein C, Minuk GY. Effects of daily, light and moderate-heavy ethanol exposure on extent of hepatic injury and recovery following toxin-induced acute hepatitis in rats.
Dig Dis Sci 2003; 48: 926-31.
61. *Sinha SK, Martin B, Gold BD, Song Q, Sargent M, Bernstein CN. The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community: And the potential for parent-to-child-transmission. Helicobacter 2004; 9: 59-68.
62. *Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the US: A profile of time since diagnosis. American Journal of Gastroenterology 2004; 99(4):650-5.
63. Bernstein CN, Blanchard JF, Rawsthorne P, Collins MT. A population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease and ulcerative colitis. Journal of Clinical Microbiology 2004; 42:1129-1135.
64. Sands BE, Anderson FH, Bernstein CN, Chey W, Feagan BG, Fedorak RN, Kamm M, Korzenik JR, Lashner BA, Onken J, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease (ACCENT II). New England Journal of Medicine 2004;350: 876-85.
65. *Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and complementary medicine use in inflammatory bowel disease: How does its use relate to use of conventional practitioners? American Journal of Gastroenterology 2004; 99: 889-93.
66. Streutker C, Bernstein CN, Chan VL, Riddell RH, Croitoru K. PCR analysis for species-specific Ribosomal DNA detects Helicobacter species DNA in intestinal tissues from patients with inflammatory bowel disease. Journal of Clinical Microbiology 2004; 42: 660-664.
67. Mayne M, Moffatt T, Kong H, McLaren PJ, Fowke KR, Becker K, Namaka M, Schenck A, Mandel JL, Bernstein CN, Melanson M. CYFIP2 regulates CD4+ T cell adhesion. European Journal of Immunology 2004; 34: 1217-27.
68. Nabalamba A, Bernstein CN, Seko C. Inflammatory bowel disease-trends in hospitalization. Health Reports 2004; 15: 25-40.
69. *Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. American Journal of Gastroenterology 2004; 99: 1744-8.
70. Robert ME, Skacel M, Ullman T, Bernstein CN, Easley K, Goldblum JR. Patterns of colonic involvement at initial presentation in ulcerative colitis: A retrospective study of 46 newly diagnosed patients. American Journal of Clinical Pathology 2004; 122: 94-9.
71. *Cantor M, Nickerson P, Bernstein CN. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. American Journal of Gastroenterology 2005; 100:1134-42.
72. *Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clinical Gastroenterology and Hepatology 2005; 3: 237-47.
73. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumor necrosis factor-a, in patients with corticosteroid-dependent Crohn’s disease. Alimentary Pharmacology and Therapeutics 2005; 21: 373-84.
74. Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn’s disease: A population based case control study. Inflammatory Bowel Diseases 2005; 11: 325-330.
75. Eckburg P, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson K, Relman DA. Diversity of the human intestinal microbial flora. Science 2005; 308:1635-1638.
76. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in IBD: A population-based study. Gastroenterology 2005; 129:827-36.
77. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A; CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of Certolizumab Pegol (CDP870) for treatment of Crohn's Disease. Gastroenterology. 2005;129: 807-818.
78. Bernstein CN, Greenberg H, Boult I, Chubey S, Leblanc C, Ryner L. A prospective comparison study of MRI versus small bowel follow through in recurrent Crohn’s disease. American Journal of Gastroenterology 2005; 100: 2493-502.
79. *Kaila B, Orr K, Bernstein CN. The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: Accurate in identifying cases of Crohn's disease and predicting inflammatory disease. Canadian Journal of Gastroenterology, 2005; 19: 717-21.
80. Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: A population-based study. American Journal of Gastroenterology 2006; 101:110-8.
81. *Green C, Elliott L, Beaudoin C, Bernstein CN. An ecological population-based study of IBD: Searching for etiological clues. American Journal of Epidemiology 2006 (in press.).
82. Bernstein CN, Rawsthorne, P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. American Journal of Gastroenterology 2006; 101(5):993-1002.
83. *Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, McPhail C, Rogala L, Miller N, Bernstein CN. The Manitoba IBD Cohort study: Prolonged symptoms before diagnosis-How much is IBS? Clinical Gastroenterology and Hepatology 2006; 4: 614-20.
84. Raza M, Bernstein CN, Ilnyckyj A. A survey of Canadian physician's choices for their own colon cancer screening. Canadian Journal of Gastroenterology 2006; 20: 281-4.
85. Schreiber S, Feagan B, D’Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J for the BIRB 796 Study Group. Oral p38 mitogen activated protein kinase (MAPK) inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clinical Gastroenterology and Hepatology 2006; 4:325-34.
86. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF. The epidemiology of inflammatory bowel disease in Canada: A population-based study: A population-based study. American Journal of Gastroenterology 2006; 101:1559-68.
*87. Longobardi T, Bernstein CN. Health care resource utilization in IBD. Clinical Gastroenterology and Hepatology 2006; 4:731-43.
*88. Tang L, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clinical Gastroenterology and Hepatology 2006; 4: 1130-4.
89. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination. Evidence for a 10 year interval between colonoscopies. JAMA 2006; 295: 2366-73.
90. Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, Jakul L, McPhail C, Ediger J, Bernstein CN. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clinical Gastroenterology and Hepatology 2006; 4:1491-1501.
91. Brant S, Wang M-H, Rawsthorne P, Sargent M, Datta LW, Nouvet F, Shugart YY, Bernstein CN. A population-based case control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. American Journal of Gastroenterology 2007; 102: 313-23.
92. Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition 2006; 22: 1210-1213.
93. Kotlowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007; 56: 669-75.
94. Bernstein CN, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. American Journal of Gastroenterology 2007; 102: 338-43.
95. Singh H, Targownik LE, Ward G, Minuk GY, Bernstein CN. An assessment of endoscopic and concomitant management of acute variceal bleeding at a tertiary care centre. Canadian Journal of Gastroenterology 2007; 21: 89-95.
96. Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Canadian Journal of Gastroenterology 2007 (in press).
97. *Chami G, Raza M, Bernstein CN. The usefulness and impact on management of positive and negative capsule endoscopy. Canadian Journal of Gastroenterology 2007 (in press).
98. Bernstein CN, Rawsthorne P, Blanchard JF. A population-based case control study of measles, mumps and rubella and inflammatory bowel disease. Inflammatory Bowel Diseases 2007;13: 759-762.
99. Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and non-inflamed gut biopsy tissues in inflammatory bowel disease. Inflammatory Bowel Diseases 2007:13: 675-683.
100. Bernstein CN, Wang MH, Sargent M, Brant SR, Collins MT. Testing the interaction between NOD-2 status and serological response to Mycobacterium paratuberculosis in IBD. Journal of Clinical Microbiology 2007; 45: 968-71.
101. *Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, McPhail C, Deering K, Bernstein CN. Predictors of medication adherence in inflammatory bowel disease. American Journal of Gastroenterology 2007 (in press).
102. *Vagianos K, Bector S, J McConnell, Bernstein CN. Nutritional assessment of patients with inflammatory bowel disease. Journal of Parenteral and Enteral Nutrition 2007; 31: 311-9.
103. Longobardi T and Bernstein CN. Utilization of health care resources by patients with IBD in Manitoba: A profile of time since diagnosis. American Journal of Gastroenterology 2007 (in press).
104. *Paski S, Wightman R, Robert M, Bernstein CN. The importance of recognizing increased cecal inflammation in health and avoiding the misdiagnosis of nonspecific colitis. American Journal of Gastroenterology 2007 (in press).
Case Reports
1. Bernstein C, McGoey J, Lertzman M. Recurrent bronchial carcinoid tumor. Chest 1989; 95; 693-4.
2. Bernstein CN, Snape WJ Jr. Active idiopathic ulcerative colitis in a patient with ongoing HIV related immunodepression. American Journal of Gastroenterology 1991; 86: 907-10.
3. Bernstein CN, Snape WJ Jr. Achalasia and development of benign esophagobronchial fistula. Digestive Diseases and Science 1992; 37; 609-12.
4. Busuttil RW, Farmer DG, Shaked A, Rolandelli R, Colonna JO, Jurin O, Colquhoun SD, Bernstein C, Shanahan F, Robert M, Goldstein LI, McDiarmid SV. Successful combined liver and small intestine transplantation for short bowel syndrome and liver failure. Western Journal of Medicine 1993: 158; 184-8.
5. Bernstein CN, Kolodny M, Block E, Shanahan F. Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids. American Journal of Gastroenterology 1993: 88; 574-7.
6. *Freilich BL, Bernstein CN. Vasculitis possibly confined to the small and large intestine. Western Journal of Medicine 1995; 162: 63-65.
7. *Pimental M, Johnston J, Allen D, Greenberg H, Bernstein CN. Primary adrenal lymphoma with associated adrenal insufficiency: A distinct entity. Leukemia and Lymphoma 1996; 24; 363-367.
8. *Ilnyckyj A, Greenberg H, Bernstein CN. Escherichia coli 0157:H7 infection mimicking Crohn's disease. Gastroenterology 1997; 112: 995-999.
9. Bernstein CN, Pettigrew N, Wang KK, Greenberg H, Lipschitz J. Multifocal gastric neoplasia after recurrent laser therapy for the watermelon stomach. Canadian Journal of Gastroenterology 1997; 11: 403-406.
10. *Ilnyckyj A, Aldor TAM, Warrington R, Bernstein CN. Crohn's disease and the Melkersson-Rosenthal Syndrome. Canadian Journal of Gastroenterology 1999; 13: 152-154.
11. *Ilnyckyj A, Hosking DH, Pettigrew NM, Bernstein CN. Extracorporeal shock wave lithotripsy causing colonic injury. Digestive Diseases and Sciences 1999; 44: 2485-2488.
12. *Khan A, Illiffe G, Houston DS, Bernstein CN. Osteonecrosis in Crohn’s disease unrelated to corticosteroid use. Canadian Journal of Gastroenterology 2001; 15: 765-68.
13. *Kaila B, D Grant, Pettigrew N, Greenberg H, Bernstein CN. Crohn's disease recurrence in a small bowel transplant. American Journal of Gastroenterology 2004; 99:158-162.
Editorials, Reviews, Opinion Papers
1. Bernstein CN, Shanahan F. Metronidazole in Crohn’s disease: What’s the score? Gastroenterology 1992; 102; 1435-6.
2. Shanahan F, Bernstein CN. Neutrophils, interleukin-8 and acute inflammation. Gastroenterology 1992; 103: 341-3.
3. Bernstein CN, Shanahan F. Braving the elementals in Crohn’s disease. Gastroenterology 1992; 103: 1363-4.
4. Shanahan F, Bernstein CN. Odd forms of inflammatory bowel disease - what can they tell us? Gastroenterology 1993; 104: 327-9.
5. Bernstein CN, Shanahan F. Purine analogues and ulcerative colitis. Gastroenterology 1993; 104: 325-6.
6. Bernstein CN, Shanahan F. Immunosuppressive and immunomodulatory therapy for inflammatory bowel disease. Canadian Journal of Gastroenterology 1993; 7: 115-120.
7. Bernstein CN, Shanahan F. Factor XIII: Is it a factor in Crohn's disease?
Gastroenterology 1993: 105; 605-607.
8. Shanahan F, Bernstein CN. ANCAs aweigh in colitis. Gastroenterology 1993: 105; 946-947.
9. Shanahan F, Bernstein CN. Safety of low dose purine analogues in inflammatory bowel disease. Gastroenterology 1994; 107: 1905-1906.
10. Bernstein CN. Update of immunomodulatory therapy for inflammatory bowel disease. Canadian Journal of Gastroenterology 1994; 8: 413-416.
11. Bernstein CN. Small bowel transplantation. Scand J Gastroenterol 1995;30 (suppl 208): 118-124.
12. Bernstein CN. Immunomodulatory therapy for inflammatory bowel disease. Prairie Medical Journal. 1995; 65: 22-24.
13. Bernstein CN, Shanahan F. Cyclosporine and inflammatory bowel disease: Still more questions. Gastroenterology 1995; 108: 943-945.
14. Anisman H, Baines MG, Berczi S, Bernstein CN, Blennerhassett MG, Gorczynski RM, Greenberg AH, Kisil FT, Mathison RD, Nagy E, Nance DM, Perdue MH, Pomerantz DK, Sabbadini ER, Stanisz A, Warrington RJ. Neuroimmune mechanisms in health and disease: I. Health. Canadian Medical Association Journal 1996; 155: 867-874.
15. Anisman H, Baines MG, Berczi S, Bernstein CN, Blennerhassett MG, Gorczynski RM, Greenberg AH, Kisil FT, Mathison RD, Nagy E, Nance DM, Perdue MH, Pomerantz DK, Sabbadini ER, Stanisz A, Warrington RJ. Neuroimmune mechanisms in health and disease: II. Disease. Canadian Medical Association Journal 1996; 155: 1075-1082.
16. Bernstein CN, Shanahan F. Purine analogs in Crohn's disease: more to learn about the long term. Gastroenterology 1996: 111; 1774-1776.
17. Bernstein CN, Shanahan F. Critical appraisal of enteral nutrition in adults with Crohn's disease. American Journal of Gastroenterology 1996; 91: 2075-2079.
18. Bernstein CN. Therapeutic enteral nut
|